

Selected Innovative Medicines in Development as of October 13, 2026



Oncology (1 of 3)

DARZALEX (daratumumab) Frontline multiple myeloma transplant ineligible (CEPHEUS)	INLEXZO (gemcitabine intravesical delivery system) Non Muscle Invasive Bladder Cancer (SunRISe-1)	RYBREVANT (amivantamab) Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)
RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4)	TALVEY + TECVAYLI Relapsed Refractory Multiple Myeloma (RedirectT-1)	TALVEY + TECVAYLI Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)
TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)	TALVEY (talquetamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)	TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)
TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)	bleximenib Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)	bleximenib Acute Myeloid Leukemia (cAMeLot-3)
CARVYKTI (Ciltacabtagene autoleucel) Frontline Multiple Myeloma TNI (CARTITUDE-5)	CARVYKTI (Ciltacabtagene autoleucel) Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)	erda-iDRS (erdafitinib intravesical delivery system) Non Muscle Invasive Bladder Cancer (MoonRISe-1)
erda-iDRS (erdafitinib intravesical delivery system) High Risk Non Muscle Invasive Bladder Cancer (MoonRISe-3)	ERLEADA (apalutamide) Localized Prostate Cancer (ATLAS)	ERLEADA (apalutamide) High Risk Prostate Cancer (PROTEUS)
INLEXZO (gemcitabine intravesical delivery system) Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)	INLEXZO (gemcitabine intravesical delivery system) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)	JNJ-1900 (NBTXR3) Head and Neck Cancer Platinum Ineligible
pasritamig Metastatic Castration-Resistant Prostate Cancer (KLK2-comPAS)	pasritamig Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)	ramantamig Relapsed Refractory Multiple Myeloma (TRIllogy-4)

ramantamig Relapsed Refractory Multiple Myeloma (TRIllogy-5)
RYBREVANT (amivantamab) Colorectal Cancer 2L (ORIGAMI-3)
TECVAYLI (teclistamab) TE NDMM maintenance (MajesTEC-4)
JNJ-0683 (ARX788) Breast Cancer
JNJ-1493 Hematological Malignancies
JNJ-2175 Solid Tumors
JNJ-3413 Lymphoma
JNJ-4916 Lung Cancer

ramantamig Relapsed Refractory Multiple Myeloma (TRIllogy-7)
RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-5)
TECVAYLI (teclistamab) TIE NDMM in combination with DR (MajesTEC-7)
JNJ-1900 (NBTXR3) Lung Cancer
JNJ-1900 (NBTXR3) Head and Neck Cancer Platinum Eligible
JNJ-2638 Gastrointestinal Cancer
JNJ-4306 Hematological Malignancies
JNJ-6143 (HLD-0915) Prostate Cancer

RYBREVANT (amivantamab) Colorectal Cancer (ORIGAMI-2)
TALVEY (talquetamab) TIE NDMM in combination with DR (MajesTEC-7)
bleximenib Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)
JNJ-0387 Solid Tumors
JNJ-1981 ER (Cisplatin Extended Release) Solid Tumors
JNJ-2761 Multiple Myeloma
JNJ-4362 (HLD-0117) Breast Cancer
JNJ-6692 Hematological Malignancies

Oncology (3 of 3)

JNJ-7446
Lung Cancer

JNJ-8377
Lymphoma

JNJ-9968
Hematological Malignancies

JNJ-8111
Prostate Cancer

JNJ-9401
Prostate Cancer

JNJ-8177 (ARX517)
Prostate Cancer

JNJ-9892
Hematological Malignancies

Immunology

ICOTYDE (icotrokinra)

Psoriasis (ICONIC)

STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis (PSUMMIT JR)

icotrokinra

Psoriatic Arthritis (ICONIC-PsA)

nipocalimab

Systemic Lupus Erythematosus (GARDENIA)

nipocalimab

Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)

icotrokinra

Crohn's Disease (ICONIC-CD)

nipocalimab

Idiopathic Inflammatory Myopathy

JNJ-8638 (Oral FcRn)

Immunological Diseases

IMAAVY (nipocalimab)

Warm Autoimmune Hemolytic Anemia (ENERGY)

TREMFYA (guselkumab)

Pediatric Juvenile Psoriatic Arthritis

JNJ-4804 Co-antibody Therapy

Ulcerative Colitis

nipocalimab

Sjogren's Disease (DAFFODIL)

TREMFYA (guselkumab)

Pediatric Crohn's Disease (MACARONI-23)

JNJ-4804 Co-antibody Therapy

Psoriatic Arthritis

JNJ-5108

Immunological Diseases

STELARA (ustekinumab)

Pediatric Ulcerative Colitis (UNIFI JR)

icotrokinra

Ulcerative Colitis (ICONIC-UC)

JNJ-4804 Co-antibody Therapy

Crohn's Disease

nipocalimab

Hemolytic Disease of the Fetus and Newborn (AZALEA)

TREMFYA (guselkumab)

Pediatric Ulcerative Colitis (QUASAR JR)

JNJ-7528

Atopic Dermatitis

JNJ-6848

Immunological Diseases

CAPLYTA (lumateperone)
Adjunctive Treatment for Major Depressive Disorder

seltorexant
Adjunctive Treatment for Major Depressive Disorder with
Insomnia Symptoms (OARS)

ITI-1284
Alzheimer's Disease-Related Psychosis

JNJ-5120
Major Depressive Disorder

CAPLYTA (lumateperone)
Bipolar Mania

SPRAVATO (esketamine)
Major Depressive Disorder with Suicidal Ideation
Pediatrics

ITI-1284
Alzheimer's Disease-Related Agitation

CAPLYTA (lumateperone)
Pediatric Psychiatric Indications

ITI-1284
Generalized Anxiety Disorder

JNJ-2056 (tau active immunotherapy) ¹
Alzheimer's Disease (RETAIN)

Select Other Areas

UPTRAVI (selexipag)
Pediatric Pulmonary Arterial Hypertension (SALTO)

milvexian (Factor Xla)
Atrial Fibrillation

macitentan
Pulmonary Arterial Hypertension 75mg (UNISUS)

SIRTURO
Leprosy

milvexian (Factor Xla)
Secondary Stroke Prevention

SIRTURO
Tuberculosis Long Acting

¹ACImmune ACI-35.030.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 13, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: ACImmune SA; SPRAVATO: Icahn School of Medicine at Mount Sinai, National Institutes of Health & Yale University; CAPLYTA: Bristol Myers Squibb; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sload Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; LAZCLUZE: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CART-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); JNJ-5120: Contineum Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited